Steve B. Warnecke

Steve B. Warnecke

Chairman of the Board

Mr. Warnecke currently serves as CEO of Evolutionary Genomics, Inc. (involved in gene discovery and validation for the agricultural industry) since 2010 and as Chairman of Children’s Partners Foundation (supporting Children’s Hospitals and cystic fibrosis research) since 2003. Previously, Mr. Warnecke served as Lead Independent Director/Audit Committee Chair for Evolving Systems, Inc. (NASDAQ – EVOL, an international telecom software company) from 2003 to 2011, as Chief Financial Officer/board member for Bacterin International, Inc. (BIHI.pk, a biologics and medical device company) from 2008 to 2010, Chief Financial Officer for The Children’s Hospital Foundation from 2003 to 2008, Board member of Boppy Company from 2005 to 2008, Senior Vice-President of Strategic Planning for First Data/Western Union (NYSE – FDC) from 2001 to 2002 and Chief Financial Officer for Frontier Airlines (former NASDAQ company acquired by Republic Airways) from 1999 to 2001. Mr. Warnecke graduated from the University of Iowa with a BBA in accounting, finance and management prior to spending the first twenty years of his career in the construction industry.


T. Richard Fort

T. Richard Fort, PhD

Board Member

Dr. Fort currently serves as President and COO of Cerescan, a biotechnology company focusing on functional brain imaging to assist in diagnosis of neurological diseases. Dr. Fort also manages The Fort Knocks Company, a family holding company focused on clean tech and life sciences investments. In 1995, he founded ESM, which quickly grew into the premiere enrollment center for Sylvan franchisees across the nation. ESM branched into higher education and became the leading business process outsourcer for student lifecycle services primarily in the areas of college admissions and student retention. ESM grew to 800 employees and was acquired by Xerox Corporation in July, 2011. Dr. Fort began his career in the space shuttle program at Kennedy Space Center, where he worked in Human Resource Development with a focus on leadership and total quality management. He earned a BA in psychology from Louisiana State University, an MS in experimental psychology from Northeast Louisiana University, and a PhD in organizational psychology at Walden University.


dr mark lupa vetdc

Mark Lupa, PhD

Board Member

Dr. Lupa holds a Bachelor’s of Science degree from Northwestern University, a Master’s degree from the University of Sussex (England) in Biomedical Engineering and completed his doctoral program in Pharmacology from the University of Lund, Sweden. He conducted neuroscience research for 15 years at institutions worldwide, including the University of Colorado and the University of California San Francisco. Dr. Lupa’s business experience came first in the brewing industry as founder, CEO and CFO of Tabernash Brewing Company, which was formed in 1993 and merged with Left Hand Brewing in 1998. Dr. Lupa then moved to the private investment company Tango to focus on technology and Life Science investments. He is currently Managing Director of High Country Venture, a venture capital fund in Boulder, Colorado, and has served as founding member of the Board of Directors of Taligen Therapeutics, Sierra Neuropharma, Oberon, DCS Surgical, and Theratogs. Dr. Lupa also served as CFO of Taligen from inception of the company in 2004 until early 2008.


johnadams

John Q. Adams, Sr.

Board Advisor

Mr. Adams serves as President of J.Q Enterprises, a holding company in real estate and ranching. Mr. Adams had a long career in the pharmaceutical industry and has owned three companies: Baylor Laboratories, sold to Norwich Eaton Pharmaceuticals; his second company, Allerderm, Inc., sold to Virbac Inc. in France; and Adams Laboratories, a private pharmaceutical company focused on respiratory therapy, sold to Medeva Pharmaceuticals, where from 1991 to 1995, Mr. Adams served as President of Medeva Americas. Mr. Adams later repurchased Adams Laboratories from Medeva and served as Chairman and Chief Executive Officer. He currently serves as Chairman of Adams Laboratories. Mr. Adams served as Chairman of Adams Respiratory Therapeutics Inc., until October 14, 2005. He has been Vice Chairman of CereScan, Inc. since June 2009 and its Director since March 2009. Mr. Adams serves as Director of Respirics, Inc. He served as a Director of Adamis Pharmaceuticals Corp. from November 2003 to June 19, 2009. Mr. Adams served as Director of Medeva Americas. He served as a Director of Cellegy Pharmaceuticals Inc., since November 6, 2003. He served as a Director of Adams Respiratory Therapeutics Inc. (Formerly Adams Laboratories, Inc) since 1997. He also retains memberships and board positions in several professional and philanthropic organizations including the American College of Allergy and the Vanderbilt University Voice Center. In July 2007, he was elected to the Board of Trustees for Heidelberg College in Tiffin, OH and in April 2009 was inducted into the Hall of Excellence of the Ohio Foundation of Independent Colleges which each year honors three distinguished graduates from 34 Ohio colleges. He is also an Honorary Fellow of the American Academy of Otolaryncology-Head and Neck Surgery. Mr. Adams holds a Degree in Biology from Heidelberg College.


Richard C. Duke, Ph.D.

Richard C. Duke, Ph.D.

Board Observer

Dr. Duke is a biotechnology executive, inventor, and serial entrepreneur with nearly fifteen years of experience in building, financing, and managing start-up biotechnology companies plus over twenty-five years of experience in biomedical research. He currently serves as CEO of Peptivir, a biopharmaceutical company developing a ‘universal’ vaccine platform. Dr. Duke is a Co-Founder and former CEO and President of GlobeImmune and has been involved in the formation of ApopLogic Pharmaceuticals, Sierra Neuropharmaceuticals, Newellink and MenoGeniX. These companies have raised more than $100 million in financing to date and have multiple products in human clinical trials. He is currently President and CEO of the Colorado Institute for Drug Device and Diagnostic Development and is a tenured faculty member in the University of Colorado Department of Medicine.


Steven Roy, MBA

Steven Roy, MBA

President and CEO, Board Member
Read Bio >>

 


Terry Opgenorth, Ph.D.

Terry Opgenorth, Ph.D.

Chief Scientific Officer, Board Observer
Read Bio >>